BOSTON — An increase in immune checkpoint proteins was observed in metastatic melanoma patients treated with topical diphencyprone, according to a study presented at the American Academy of Dermatology Annual Meeting.“Diphencyprone, or DCPD for short, has been used for many years to treat various dermatologic conditions including alopecia areata and warts, but more recently it’s

Related Keywords

Boston , Massachusetts , United States , American , Rebeccal Forand , Nicholas Gulati , American Academy Of Dermatology Annual Meeting , Icahn School Of Medicine , American Academy , Dermatology Annual Meeting , Dermatology Annual , Icahn School , Mount Sinai ,